Shandong Weigao Orthopaedic Device Co Ltd
SSE:688161
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (43.4), the stock would be worth ¥46.02 (46% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 29.7 | ¥31.55 |
0%
|
| 3-Year Average | 43.4 | ¥46.02 |
+46%
|
| 5-Year Average | 34.4 | ¥36.5 |
+16%
|
| Industry Average | 20.3 | ¥21.58 |
-32%
|
| Country Average | 20.8 | ¥22.09 |
-30%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
S
|
Shandong Weigao Orthopaedic Device Co Ltd
SSE:688161
|
12.6B CNY | 29.7 | 46.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 54.5 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 16.6 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 27 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 17.4 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 22.3 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 15.6 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 28.1 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 38.5 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 17.5 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.2 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
Shandong Weigao Orthopaedic Device Co Ltd
Glance View
Nestled in the bustling economic landscape of China, Shandong Weigao Orthopaedic Device Co Ltd has carved a respected niche for itself in the realm of medical equipment. The company, founded as a subsidiary of the larger Weigao Group, specializes in the design, production, and distribution of orthopedic devices. Its journey starts with an unwavering commitment to incorporating advanced technology into healthcare solutions. Shandong Weigao has honed its focus on spinal, trauma, and joint-related products, ensuring that its offerings meet international standards and cater to both domestic and global markets. Operating within an industry where precision and reliability are paramount, the company has leveraged a well-established network to distribute its products to hospitals, clinics, and healthcare facilities, thus embedding its roots deeply within the healthcare infrastructure. This thriving enterprise makes money by delivering value through its diverse product portfolio tailored to meet the complex and varied needs of orthopedic treatments. Its revenue model is centered around a combination of direct sales, strategic partnerships, and long-term contracts with healthcare providers. By engaging in continuous research and development, Shandong Weigao not only expands its product lines but also enhances existing solutions, ensuring they remain cutting-edge. This emphasis on innovation has enabled the company to maintain a competitive edge in a rapidly evolving market, positioning itself as a leader in China’s orthopedic device industry. Through strategic market penetration and an adept understanding of regulatory landscapes, Shandong Weigao Orthopaedic Device Co Ltd not only sustains its growth but also contributes significantly to the advancements in orthopedic healthcare.